Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 2
1996 2
1997 3
1998 3
1999 2
2000 7
2001 2
2002 2
2003 3
2004 4
2005 10
2006 7
2007 5
2008 6
2009 10
2010 11
2011 8
2012 10
2013 12
2014 20
2015 24
2016 44
2017 57
2018 73
2019 89
2020 128
2021 128
2022 118
2023 98
2024 55

Text availability

Article attribute

Article type

Publication date

Search Results

824 results

Results by year

Filters applied: . Clear all
Page 1
The pancreatic cancer genome revisited.
Hayashi A, Hong J, Iacobuzio-Donahue CA. Hayashi A, et al. Nat Rev Gastroenterol Hepatol. 2021 Jul;18(7):469-481. doi: 10.1038/s41575-021-00463-z. Epub 2021 Jun 4. Nat Rev Gastroenterol Hepatol. 2021. PMID: 34089011 Review.
Pancreatic cancer is a genetic disease, and the recurrent genetic alterations characteristic of pancreatic cancer indicate the cellular processes that are targeted for malignant transformation. ...Wild-type KRAS pancreatic cancers, some of which are driven by …
Pancreatic cancer is a genetic disease, and the recurrent genetic alterations characteristic of pancreatic cancer indicate the …
Identifying patients with NTRK fusion cancer.
Solomon JP, Benayed R, Hechtman JF, Ladanyi M. Solomon JP, et al. Ann Oncol. 2019 Nov 1;30(Suppl_8):viii16-viii22. doi: 10.1093/annonc/mdz384. Ann Oncol. 2019. PMID: 31738428 Free PMC article. Review.
Due to the efficacy of tropomyosin receptor kinase (TRK) inhibitor therapy and the recent Food and Drug Administration approval of larotrectinib, it is now clinically important to accurately and efficiently identify patients with neurotrophic TRK (NTRK) fusion-driven cancer …
Due to the efficacy of tropomyosin receptor kinase (TRK) inhibitor therapy and the recent Food and Drug Administration approval of larotrect …
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Mizuta H, Okada K, Araki M, Adachi J, Takemoto A, Kutkowska J, Maruyama K, Yanagitani N, Oh-Hara T, Watanabe K, Tamai K, Friboulet L, Katayama K, Ma B, Sasakura Y, Sagae Y, Kukimoto-Niino M, Shirouzu M, Takagi S, Simizu S, Nishio M, Okuno Y, Fujita N, Katayama R. Mizuta H, et al. Nat Commun. 2021 Feb 24;12(1):1261. doi: 10.1038/s41467-021-21396-w. Nat Commun. 2021. PMID: 33627640 Free PMC article.
ALK gene rearrangement was observed in 3%-5% of non-small cell lung cancer patients, and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. ...In addition, gilteritinib was effective against NTRK-rearranged cancers including entrectinib-resi …
ALK gene rearrangement was observed in 3%-5% of non-small cell lung cancer patients, and multiple ALK-tyrosine kinase inhibitors (TKI …
NTRK fusion-positive cancers and TRK inhibitor therapy.
Cocco E, Scaltriti M, Drilon A. Cocco E, et al. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. doi: 10.1038/s41571-018-0113-0. Nat Rev Clin Oncol. 2018. PMID: 30333516 Free PMC article. Review.
NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and paediatric tumour types. ...Despite durable disease control in many patients, advanced-stage NTRK fus …
NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin receptors TRKA, TRKB and TRKC, respectively) are …
Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.
Nikiforova MN, Mercurio S, Wald AI, Barbi de Moura M, Callenberg K, Santana-Santos L, Gooding WE, Yip L, Ferris RL, Nikiforov YE. Nikiforova MN, et al. Cancer. 2018 Apr 15;124(8):1682-1690. doi: 10.1002/cncr.31245. Epub 2018 Jan 18. Cancer. 2018. PMID: 29345728 Free PMC article.
GC cutoffs were established to distinguish cancer from benign nodules with 93.9% sensitivity, 89.4% specificity, and 92.1% accuracy. ...Cancer 2018;124:1682-90. 2018 American Cancer Society....
GC cutoffs were established to distinguish cancer from benign nodules with 93.9% sensitivity, 89.4% specificity, and 92.1% accuracy. …
NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.
Lee YA, Lee H, Im SW, Song YS, Oh DY, Kang HJ, Won JK, Jung KC, Kwon D, Chung EJ, Hah JH, Paeng JC, Kim JH, Choi J, Kim OH, Oh JM, Ahn BC, Wirth LJ, Shin CH, Kim JI, Park YJ. Lee YA, et al. J Clin Invest. 2021 Sep 15;131(18):e144847. doi: 10.1172/JCI144847. J Clin Invest. 2021. PMID: 34237031 Free PMC article.
BACKGROUNDMolecular characterization in pediatric papillary thyroid cancer (PTC), distinct from adult PTC, is important for developing molecularly targeted therapies for progressive radioiodine-refractory (131I-refractory) PTC.METHODSPTC samples from 106 pediatric patients …
BACKGROUNDMolecular characterization in pediatric papillary thyroid cancer (PTC), distinct from adult PTC, is important for developin …
Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer.
Xia H, Xue X, Ding H, Ou Q, Wu X, Nagasaka M, Shao YW, Hu X, Ou SI. Xia H, et al. Clin Lung Cancer. 2020 May;21(3):247-254. doi: 10.1016/j.cllc.2019.09.004. Epub 2019 Sep 26. Clin Lung Cancer. 2020. PMID: 31761448
Additionally, 1 unique rearrangement occurred upstream of the transcription start site of BCL9 fused to exon 12 of NTRK1 (intragenic region, BCL9-NTRK1). Of the 12 cases of NTRK1+ lung cancer, 6 had had concurrent activating EGFR mutations and/or had r …
Additionally, 1 unique rearrangement occurred upstream of the transcription start site of BCL9 fused to exon 12 of NTRK1 (intragenic …
Anchored multiplex PCR for targeted next-generation sequencing.
Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD, Chen J, Robinson HE, Shim HS, Chmielecki J, Pao W, Engelman JA, Iafrate AJ, Le LP. Zheng Z, et al. Nat Med. 2014 Dec;20(12):1479-84. doi: 10.1038/nm.3729. Epub 2014 Nov 10. Nat Med. 2014. PMID: 25384085
On the basis of our experience with performing AMP on 986 clinical FFPE samples, we show its potential as both a robust clinical assay and a powerful discovery tool, which we used to identify new therapeutically important gene fusions: ARHGEF2-NTRK1 and CHTOP-NTRK1 …
On the basis of our experience with performing AMP on 986 clinical FFPE samples, we show its potential as both a robust clinical assay and a …
Paediatric-type diffuse high-grade gliomas in the 5th CNS WHO Classification.
Gianno F, Giovannoni I, Cafferata B, Diomedi-Camassei F, Minasi S, Barresi S, Buttarelli FR, Alesi V, Cardoni A, Antonelli M, Puggioni C, Colafati GS, Carai A, Vinci M, Mastronuzzi A, Miele E, Alaggio R, Giangaspero F, Rossi S. Gianno F, et al. Pathologica. 2022 Dec;114(6):422-435. doi: 10.32074/1591-951X-830. Pathologica. 2022. PMID: 36534421 Free PMC article. Review.
NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer.
Park DY, Choi C, Shin E, Lee JH, Kwon CH, Jo HJ, Kim HR, Kim HS, Oh N, Lee JS, Park OK, Park E, Park J, Shin JY, Kim JI, Seo JS, Park HD, Park J. Park DY, et al. Oncotarget. 2016 Feb 16;7(7):8399-412. doi: 10.18632/oncotarget.6724. Oncotarget. 2016. PMID: 26716414 Free PMC article.
Here we identified recurrent LMNA-NTRK1 and TPM3-NTRK1 fusions in Korean patients with colon cancer (3 out of 147, 2%) through next-generation RNA sequencing (RNA-seq). NTRK1 fusions were mutually exclusive oncogenic drivers of colon cancer that …
Here we identified recurrent LMNA-NTRK1 and TPM3-NTRK1 fusions in Korean patients with colon cancer (3 out of 147, 2%) …
824 results